Interim Petosemtamab Data in Metastatic CRC Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety October 29, 2025
Positive Ph 2 Results for HBM4003 and Tislelizumab Combination in MSS mCRC announced October 29, 2025
Results for HLD-0915 Demonstrate Encouraging Safety and Anti-Tumor Activity in Metastatic CRPC October 29, 2025
Rare Pediatric Disease Designation from FDA for Iopofosine I 131 in R/R Pediatric High-Grade Glioma October 29, 2025
Type C meeting with FDA requested to discuss OS findings in 1L GBM patients treated with paxalisib and to discuss potential regulatory pathway per OCE’s Project FrontRunner initiative October 29, 2025
BLA submission planned in Q4 2025 for Ivonescimab based on HARMONi Global Ph 3 Study Results October 29, 2025
FDA Approves Revuforj® (revumenib) in Adult & Pediatric Patients with R/R NPM1 Mutated AML October 29, 2025
